Marinus Pharma (MRNS) to Offer Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Marinus. Marinus has granted the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares offered in the public offering.

Cantor Fitzgerald & Co. is acting as sole bookrunner for the proposed offering.

Marinus intends to use the net proceeds of the offering to fund the development of its product candidates and for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, acquisitions of new technologies, products or businesses, and investments.

You May Also Be Interested In

• Nuvation Bio prices $250M convertible notes offering due 2032
• CrowdStrike (CRWD) Reiterated at Overweight by Cantor Fitzgerald on Modest Beat
• ProQR prices $50M share offering with Eli Lilly joining as buyer